HR Execs on the Move

Eterna Therapeutics

www.eternatx.com

 
Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.eternatx.com
  • 1035 Cambridge Street Suite 18A
    Cambridge, MA USA 02141
  • Phone: 212.582.1199

Executives

Name Title Contact Details

Similar Companies

ImmunityBio

ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company`s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. We are applying our science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

PrimeGen Biotech

PrimeGen Biotech LLC is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Nkmax

NKMax America is harnessing the power of the body`s immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient`s ability to destroy abnormal cells.

BridgeBio

We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.

Vyriad

At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.